BLI Banque de Luxembourg Investments Reduces Position in Insulet Corporation $PODD

BLI Banque de Luxembourg Investments cut its position in shares of Insulet Corporation (NASDAQ:PODD) by 71.3% in the fourth quarter, Holdings Channel.com reports. The firm owned 5,002 shares of the medical instruments supplier’s stock after selling 12,398 shares during the quarter. BLI Banque de Luxembourg Investments’ holdings in Insulet were worth $1,436,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in PODD. NewEdge Advisors LLC boosted its stake in shares of Insulet by 44.8% during the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 64 shares during the period. Cresset Asset Management LLC boosted its stake in shares of Insulet by 7.3% during the 2nd quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock worth $813,000 after purchasing an additional 177 shares during the period. Cerity Partners LLC boosted its stake in shares of Insulet by 68.7% during the 2nd quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock worth $5,423,000 after purchasing an additional 7,030 shares during the period. Sei Investments Co. boosted its stake in shares of Insulet by 27.4% during the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock worth $43,245,000 after purchasing an additional 29,584 shares during the period. Finally, Treasurer of the State of North Carolina boosted its stake in shares of Insulet by 2.5% during the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock worth $10,290,000 after purchasing an additional 791 shares during the period.

Insider Buying and Selling at Insulet

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PODD. Evercore dropped their price target on shares of Insulet from $240.00 to $200.00 in a research note on Thursday, May 7th. Weiss Ratings cut shares of Insulet from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 15th. Truist Financial lowered their price objective on shares of Insulet from $315.00 to $250.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. BTIG Research lowered their price objective on shares of Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a research report on Tuesday, May 26th. Finally, Wells Fargo & Company lowered their price objective on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Twenty-one research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $250.00.

Insulet Price Performance

Insulet stock opened at $159.61 on Wednesday. The stock has a market cap of $11.05 billion, a price-to-earnings ratio of 37.12, a price-to-earnings-growth ratio of 1.19 and a beta of 1.13. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. Insulet Corporation has a 1 year low of $140.63 and a 1 year high of $354.88. The firm has a 50-day moving average of $173.43 and a two-hundred day moving average of $235.68.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, research analysts forecast that Insulet Corporation will post 6.46 earnings per share for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.